Management of Acute Heart Failure: Contribution of Ultrasound Daily "in Bed Patient" Adjustment on Therapy With Impact Measure on re Hospital Rate During 30 Days

Inclusion Criteria: The patient or his representative must be given free and informed consent and signed consent. * The patient must be affiliated or beneficiary of a health insurance plan. * The patient is available for a follow-up 6 months. * The patient is of age or older (\>) 18. * Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV. * Patient with impaired LVEF \<50%. * Patient with Nt-proBNP values\> 1200pg / ml. Exclusion Criteria: * The subject takes part in another study. * The subject is exclusion period determined by a previous study. * The subject is under judicial protection. * The subject or his representative refuses to sign the consent. * It is not possible to give the subject or his representative informed information. Non-inclusion criteria for those diseases or conditions associated (s) interfere (s): * The patient is pregnant or is breastfeeding. * The patient is already included in a surveillance program (PRADO, OSICAT). * Patient with a mechanical or biological mitral prosthesis. * History of mitral stenosis. * severe valvular surgery with maturity in months (\<30 days). * chronic renal impairment on dialysis. * High grade AV block (AVB and BAV3 2/1). * Hypertrophic cardiomyopathy. * Cardiogenic shock. * Contraindications to furosemide.